Leukemia Clinical Trials in Tennessee

Showing 621-640 of 1,520 trials

First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349

The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Metastatic or Locally Advanced Unresectable Solid Tumors

EMD Serono Research & Development Institute, Inc.15 participantsStarted Mar 2022

Hackensack, New Jersey, United States • Nashville, Tennessee, United States • Toronto, Canada

TERMINATEDPhase 129 miles

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

NCT03166631

The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for further development of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and to evaluate its safety and tolerability by monitoring the occurrence and severity of adverse events (AEs). Secondary objectives are the determination of the pharmacokinetic (PK) profile of BI 891065 monotherapy as well as of BI 891065 in combination with BI 754091, and the preliminary assessment of anti-tumour activity.

NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung

Boehringer Ingelheim62 participantsStarted Sep 2017

Sarasota, Florida, United States • Nashville, Tennessee, United States • Milwaukee, Wisconsin, United States

COMPLETEDPhase 1/229 miles

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

NCT02614066

The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Kite, A Gilead Company125 participantsStarted Mar 2016

La Jolla, California, United States • Los Angeles, California, United States • Orange, California, United States +30 more locations

First in Human Study of M1069 in Advanced Solid Tumors

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Leukemia Trials in Other Cities

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Pediatric Cardiac Output Monitoring Observational Study

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Other Conditions in Tennessee